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Polyubiquitylation leading to proteasomal degradation is a well-established mechanism for regulat-
ing TGF-b signal transduction components such as receptors and Smads. Recently, an equally impor-
tant role was suggested for monoubiquitylation of both Smad4 and receptor-associated Smads that
regulates their function without protein degradation. Monoubiquitylation of Smads was discovered
following the identiﬁcation of deubiquitylases required for TGF-b signaling, suggesting that contin-
uous cycles of Smad mono- and deubiquitylation are required for proper TGF-b signal transduction.
Here we summarize and discuss recent work on Smad mono- and deubiquitylation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Smads, thereby regulating cellular responsiveness to TGF-b signals.Members of the TGF-b family of proteins are pleiotropic cell sig-
naling molecules involved in many fundamental biological pro-
cesses. These include the induction of the embryonic germ layers,
patterning the axes of the body plan and maintenance of homeo-
stasis in adult tissues [1]. Mirroring these multiple roles, defects
in TGF-b signaling are associated with both developmental and
adult syndromes such as birth defects, tissue ﬁbrosis and cancer
[2]. Mechanisms underlying the transduction of TGF-b signals from
the cell membrane to the nucleus have been extensively character-
ized and reviewed elsewhere [3,4]. Brieﬂy, secreted TGF-b ligands
engage in a complex with two transmembrane kinase receptors
leading one member of the receptor complex to phosphorylate
C-terminal serine residues of R-Smads (Receptor-associated Smad
signal transducers). Phosphorylation enables R-Smads to accumu-
late in the nucleus where they form a DNA binding complex with
their sibling protein Smad4. This Smad heteromeric complex regu-
lates gene-expression in conjunction with promoter-speciﬁc
transcription factors and cofactors. This basic scenario is shared be-
tween the TGF-b/Activin/Nodal and Dpp/BMP subfamilies of TGF-b
family ligands, although each subfamily employs a different set of
R-Smads (Smad2/3 or Smad1/5/8, respectively).
A growing number of studies have shown that numerous mech-
anisms ensure tight control over the activity of receptors andchemical Societies. Published by E
S. Dupont), +1 480 965 6899
Dupont), newfeld@asu.eduSome of these strategies inﬂuence the primary phosphorylation
events of the signaling cascade, such as receptor and R-Smad phos-
phorylation [5] while others involve a variety of post-translational
modiﬁcations to pathway components. In the case of Smads these
modiﬁcations include additional phosphorylation events [6,7],
sumoylation [8], parpylation [9], acetylation [10] and ubiquityla-
tion [11,12].
Ubiquitin entered our understanding of TGF-b signaling when
the mammalian HECT-domain ubiquitin ligases, Smurf1 and
Smurf2, were discovered as negative regulators of the pathway
[13,14]. Subsequently other molecules with E3 ubiquitin ligase
activity were isolated that regulate TGF-b signaling. These include
additional HECT-domain family members (e.g., Nedd4L, Wwp1/
Tiul1 and Aip4/Itch; 12) and RING-domain proteins such as
Arkadia, Highwire and Ectodermin/Tif1-c/Trim33 [15–17]. These
molecules, except Arkadia, were isolated as inhibitors of TGF-b
signaling thus assigning to ubiquitylation a predominantly nega-
tive role in the TGF-b cascade. The role of polyubiquitylation and
degradation in TGF-b signaling is well known [12]. Here we discuss
technical issues related to the analysis of monoubiquitylation and
recent data revealing the role of mono- and deubiquitylation in the
regulation of Smad activity.
2. The basics of ubiquitylation
Ubiquitylation is a regulatory mechanism that impinges on a
wide variety of processes including cell-cycle checkpoints, DNA
damage responses and signal transduction pathways [e.g., [18]].lsevier B.V. All rights reserved.
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tide to a target protein via the sequential action of three enzymes:
a ubiquitin activating enzyme (E1), a conjugating enzyme (E2) that
carries the activated ubiquitin and transfers it to the target protein
and a ubiquitin ligase (E3) that binds both the target and the E2 to
promote efﬁcient ubiquitin transfer.
Compared to other post-translational modiﬁcations, ubiquity-
lation is a particularly diverse process [19]. Ubiquitin can be
linked to a target protein as a monomer on a single lysine
(monoubiquitylation), as a monomer to multiple lysines (oligoub-
iquitylation), or several ubiquitin molecules can be added serially
to the same lysine forming a polyubiquitin chain. Furthermore,
polyubiquitin chains can assume different geometries according
to which of the seven internal lysines of ubiquitin (K48, K63,
K29, etc.) is used for polymerization. As a result ubiquitylation
can participate in a variety of regulatory mechanisms. For exam-
ple: (1) as a trigger for proteasomal degradation (K48-linked
polyubiquitylation), (2) as a scaffold for protein–protein interac-
tions (K63-linked polyubiquitylation in the NF-jB pathway), (3)
or as a tag for vesicle sorting during endocytosis (EGF receptor
signaling). In addition, ubiquitylation can be reversed. Cells have
at their disposal over 100 different deubiquitylating enzymes that
can remove ubiquitin from modiﬁed proteins, thus resetting the
system or enabling cells to switch from one type of ubiquitylation
to another [20].
Monoubiquitylation received particular attention in the last
decade when a number of observations in ﬁelds as disparate as
DNA repair, histone regulation, membrane receptor trafﬁcking
and regulation of tumor suppressors (such as PTEN, FOXO and
p53) pointed to a key role for monoubiquitylation as a general
modulator of protein function, rather than as a dedicated signal
for protein destruction [21,22]. In this respect, monoubiquitylation
is comparable to protein phosphorylation: it can regulate protein
activity and subcellular localization, it can form or conceal pro-
tein–protein interaction surfaces, it can be used for regulation in
a time- and space-dependent manner without the need of regulat-
ing total protein levels and it can be rapidly reversed by the activity
of deubiquitylases. Moreover, given the size of ubiquitin (76 amino
acids), monoubiquitylation could in principle enable interactions
based on the newly resulting tridimensional structure of the tar-
geted protein.3. Technical challenges in the analysis of ubiquitylation
When studying a regulatory mechanism based on ubiquityla-
tion, there are three key experimental issues to be considered:
(1) what is the relevant ubiquitylation pattern of the target –
mono-, oligo- or polyubiquitylation; (2) does ubiquitylation
regulate degradation of the target or is it regulative; and (3) in
the regulative situation - to what extent can the biological function
of the ligase (or the deubiquitylase) be explained by regulation of
the proposed target?
For the ﬁrst point (relevant ubiquitylation pattern of the target),
it is clear that studying the endogenous ubiquitylation pattern of a
protein is challenging. In rare instances, the pattern is so obvious
that the mono- or polyubiquitylated isoforms can be readily de-
tected by a simple western blot, as is the case for Hif1a or Fancd2
[23]. Generally this is not observed, even for a paradigmatic exam-
ple of ubiquitin-dependent degradation such as p53. At least in
part, this is because polyubiquitylated proteins are rapidly
degraded and because many deubiquitylases are thought to be
aspeciﬁcally activated upon cell lysis. Thus, in most cases it is nec-
essary to immunoprecipitate the protein from cell extracts and
identify double positive higher molecular weight bands with both
anti-ubiquitin and an antibody to the target protein (or its epitopetag). Even then interpretation of the results may be complicated by
the presence of other coprecipitating ubiquitylated proteins and by
the fact that available antibodies detecting endogenous ubiquitin
are often not very sensitive, such that low levels of ubiquitylation
or monoubiquitylation can be easily missed. The use of overexpres-
sed epitope-tagged ubiquitin constructs can solve the last problem,
but they introduce an extra variable. Alternatively raising antibod-
ies speciﬁc to ubiquitylated proteins would circumvent the need
for immunoprecipitation. However this approach is very difﬁcult
with only two or three antibodies available. Thus it is often hard
to assess, in a quantitative fashion, the degree of ubiquitylation
of a protein.
Once the ubiquitylation pattern has been deﬁned, the next
question is where this modiﬁcation is occurring on the target
protein (i.e. on which lysine). Bioinformatics studies of evolu-
tionary conservation can provide clues to the identity of tar-
geted lysines based on the idea that evolution will act to
conserve important regulatory interactions [24]. Alternatively
direct mapping of ubiquitylation sites can be addressed either
by systematic lysine mutation [25,26] or by mass-spectrometry
[27]. The ﬁrst approach can be complicated by the effect of
amino acid mutations that are independent from ubiquitylation
(e.g. modiﬁcation of protein structure). The second approach is
more direct but is limited to proteolytic peptides that can be
detected, so that often there are lysines that cannot be queried.
In the end, mutation of the relevant residue(s) should render
the protein insensitive, both biochemically and functionally, to
ubiquitylation.
For the second point (ubiquitylation regulates degradation of
the target or is regulative), this too can be challenging. For a few
proteins such as Hif1a, p53 and b-catenin it is self-apparent
because inhibition of the proteasome greatly enhances detection
of the polyubiquitylated protein and readily stabilizes its steady-
state levels. In general it is more difﬁcult to establish which is
the relevant process. For example, degradation may be visible
only in pulse-chase assays. Alternatively, polyubiquitylation
and degradation may be visible only upon overexpression of
the E3 ligase. Here, in the absence of supporting loss-of-function
evidence E3 overexpression can be misleading as it can mask
regulative ubiquitylation. Lastly, polyubiquitylation does not
automatically lead to degradation. For example in the NF-jB
pathway, K63-linked polyubiquitylation acts as a ‘‘scaffold’’ to
enable signal transduction [19]. Also, in the TGF-b pathway
K63-linked polyubiquitylation promoted by TRAF6 plays a key
role in the regulation of non-Smad TGF-b receptor signaling
[28–30].
For the third point (the biological function of an E3 ligase or a
deubiquitylase is dependent upon its target protein), it is essential
to identify the appropriate enzyme/target pair. In the ubiquityla-
tion reaction, target speciﬁcity is thought to be primarily deter-
mined at the level of E3 ligase/target interaction [31]. However,
E3 speciﬁcity is not absolute as one ligase can have multiple
targets. This also applies to deubiquitylases where the potential
for multiple interactions is even higher as the human genome en-
codes for over 100 deubiquitylases [23]. To determine the func-
tional enzyme/target pair one relies on both biochemical and
genetic evidence. For biochemical evidence one should observe a
requirement of the E3 ligase for ubiquitylation. For genetic evi-
dence, phenotypes due to loss of the E3 ligase should also depend
on the target and phenotypes due to loss of the target should dom-
inate those due to loss of the E3 ligase in double mutants (i.e. the
target should be epistatic to the ligase). An example of strong
genetic data supporting an enzyme/target pair is that of Mdm2
and p53: mouse knockouts for the p53 ligase Mdm2 die during
embryogenesis and are fully rescued by the concomitant knockout
of p53 [32].
Fig. 1. Smad4 regulation by mono- and deubiquitylation. (A) Opposing roles of
Ecto/Tif1-c (an E3 ligase adds a monoubiquitin that destabilizes Smad4–R-Smad
complexes – blue arrow) and FAM/Usp9x (a deubiquitylase that removes mono-
ubiquitin and allows Smad4–R-Smad complex formation – green arrow) in TGF-b
signaling. (B–D) Model for activation of Smad4 monoubiquitylation by association
with DNA. (B) Ecto/Tif1-c bound to an activated R-Smad–Smad4 complex is
recruited to Smad-binding elements (SBE) in promoter DNA. (C) The presence of
speciﬁc histone marks such as acetylation (AC), possibly induced by transcription-
ally-active Smads (green arrow), then activates Ecto ubiquitin ligase activity. (D)
Ecto/Tif1-c then monoubiquitylates Smad4 (red arrow) causing the dissociation of
the Smad complex and the cessation of transcription.
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An early example of monoubiquitylation as a mechanism
regulating Smad activity derived from studies of the E3 ligase
Ecto/Tif1-c and the deubiquitylase FAM/Usp9x [17,25]. Ecto/
Tif1-c was cloned via a cDNA overexpression screen in Xenopus
embryos looking for molecules opposing the differentiation of
ectodermal cells. Its subsequent characterization showed that
Ecto/Tif1-c is required to protect cells of the ectoderm, located in
the animal region of the embryo, from Nodal/TGF-b signals that in-
duce endoderm and mesoderm in the vegetal and equatorial
regions, respectively. Within the ectoderm, Ecto/Tif1-c restricts
BMP signaling, enabling the balanced differentiation of ectodermal
cells into epidermal and neural lineages. Accordingly, in human
cells Ecto/Tif1-c restrains both TGF-b and BMP responses.
Ecto/Tif1-c was shown to bind Smad4, the common transducer
of BMP and TGF-b signals and to promote its ubiquitylation. In
knock down experiments Ecto/Tif1-c was required for Smad4
ubiquitylation in Xenopus embryos, for nuclear exclusion of Smad4
in human cells and for the instability of the Smad4 colon tumor al-
lele R100T. Consistent with this, mutation of the RING domain of
Ecto/Tif1-c was sufﬁcient to abolish its Smad4 inhibitory activity.
Thus, Ecto/Tif1-c was proposed to act a Smad4 ubiquitin ligase
and Smad4 antagonist [33,34].
The role of Smad4 ubiquitylation as a key regulatory step in
TGF-b signaling was later substantiated by the isolation of the deu-
biquitylase FAM/Usp9x as a required factor for Smad activity. In
mammalian cells and Xenopus embryos, FAM/Usp9x sustains both
TGF-b and BMP signaling by deubiquitylating Smad4 and by coun-
teracting the inhibitory activity of Ecto/Tif1-c [25]. Smad4 is pri-
marily, though not fully, monoubiquitylated in several cellular
systems including Xenopus embryos, depending upon the endoge-
nous levels of FAM/Usp9x and of Ecto/Tif1-c. This modiﬁcation was
mapped to lysine 519 (K519) of Smad4 that is located close to an
interaction interface with R-Smads. Given its position, K519-
monoubiquitylated Smad4 is unable to form a complex with phos-
phorylated Smad2. Thus, the antagonistic activities of Ecto/Tif1-c
and FAM/Usp9x on Smad4, mono- and deubiquitylation respec-
tively, regulate active Smad complex formation and, ultimately,
TGF-b responsiveness (Fig. 1A).
Other studies also observed that Smad4 could be monoubiqui-
tylated [35,36]. One report noted that Smad4 is mainly mono- or
oligoubiquitylated, mapped this modiﬁcation to lysine 507
(K507) and proposed it as a positive input for TGF-b signaling
[35]. This interpretation was primarily based on the lack of activity
of Smad4 K507-mutants. However K507 is one of the residues of
Smad4 that bind to the phosphorylated R-Smad C-terminal tail,
such that its mutation prevents efﬁcient R-Smad/Smad4 interac-
tions [37,38]. Thus, there is the possibility of a different rationale
for the inactivity of Smad4 K507-mutants. Still, in some assays
Smad4 appears linked to two ubiquitins [35,25], with K507 per-
haps acting as an alternative or additional monoubiquitylation site
to K519. Monoubiquitylation at K507 would also interfere with
phospho-R-Smad binding and thus functionally inactivate Smad4.
Future studies are necessary to discern how these two ubiquityla-
tion events are regulated in different cellular contexts and whether
different ligases are responsible for K507 and K519 ubiquitylation.
In parallel to these studies, a bioinformatics analysis of lysine
conservation in Smad proteins identiﬁed Smad4 K507 as a lysine
that is universally conserved at the homologous position in all
Smads from nematodes, ﬂies and mice. A subgroup analysis of
mouse Smad4 and its closest relatives (ﬂy Medea and nematode
Sma-4) then identiﬁed K519 as a Smad4 speciﬁc lysine. Based on
the fact that K507 was known to be monoubiquitylated [35] itwas proposed that K519 would be as well [24]. This prediction
was subsequently validated [25].
One unsolved question related to Smad4 monoubiquitylation is
where this takes place within the cell. Two observations compound
the uncertainty: (1) although Smad4 monoubiquitylation is incom-
patible with Smad4/R-Smad interactions Ecto/Tif1-c was found in
a trimeric complex with Smad4 and phospho-Smad2, and (2) TGF-
b stimulation promoting Smad4/R-Smad complex formation
enhanced Smad4 monoubiquitylation [25]. Recently, a possible
solution to this question was provided by the discovery of a link
between Ecto/Tif1-c and the transcriptional engagement of Smads
[39]. To inhibit TGF-b signaling Ecto/Tif1-c requires not only its
RING domain but also its C-terminal PHD-B romo domain. This
domain enables Ecto/Tif1-c to bind to histones in a manner depen-
dent upon acetylation, and this in turn activates Ecto/Tif1-c
ubiquitin ligase activity for Smad4 [39]. A positive effect of the
p300 histone acetyltransferase on Smad4 monoubiquitylation
Fig. 2. Ecto/Tif1c in early mouse development. Schematic of mouse embryos with
the epiblast (progenitor of the embryo proper) in gray adjacent to extraembryonic
cells of the ectoplacental cone (EPC). The thin layer surrounding the epiblast and the
EPC is the primitive endoderm. Top row is wild type. At embryonic day 5.5 (E5.5 –
one day past uterine implantation) Nodal signaling (black arrow) induces differ-
entiation of the Distal Visceral Endoderm (DVE – in red). At E7.0, one-half day past
the initiation of gastrulation, Nodal (black arrow) induces differentiation within the
epiblast of mesodermal tissues (shades of blue). Rotation of the DVE toward the
anterior forms the Anterior Visceral Endoderm (AVE – in red) that secretes the
Nodal antagonists Lefty1 and Cerberus-like (red T-bars). These proteins limit the
activity of Nodal within the epiblast. Middle row is Ecto /. At stage E5.5. the lack
of Ecto/Tif1-c causes an expansion of the DVE and subsequently the AVE (larger red
area). The latter leads to the absence of mesoderm due to production of excess
Lefty1 and Cerberus-like (larger red T-bars). Bottom row is Ecto/ only in epiblast
cells. At stage E5.5 these embryos are indistinguishable from wild type. At stage
E7.0, AVE expression of Lefty1 and Cerberus-like is wild type but enhanced Nodal
signaling (larger black arrow) within the epiblast leads to expansion of mesoderm
(larger blue area).
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tion can be regulated by chromatin [36]. This mechanism would
allow Smad transcriptional complexes to self-limit their own activ-
ity (Fig. 1B–D). When active Smads bind a promoter in response to
TGF-b stimulation they carry with them Ecto/Tif1-c. Once bound to
chromatin Ecto/Tif1-c can be locally activated (possibly by histone
modiﬁcations induced by Smads such as acetylation), to ubiquity-
late Smad4 and destabilize the Smad complex [39]. The role of the
PHD-Bromo domain of Ecto/Tif1-c as a chromatin-interaction
module was recently observed in another study, where a distinct
histone-code for PHD-Bromo domain interaction was observed
[40]. Future studies will be required to address the possibility that
cell type speciﬁc histone-codes are responsible for distinct
activities of Ecto/Tif1-c [40,41].
RING and PHD-Bromo domains, promoting ubiquitylation and
histone reading respectively, are found in all Tif1 family members.
Tif1-a/Trim24 and KAP1/Tif1-b/Trim28 also act at the chromatin
level via their PHD-Bromo domain [42,43] and have the potential
to promote ubiquitylation through their RING-domain [44,45]. This
suggests that a general role of Tif1 proteins is connecting epige-
netic information to the regulation of transcription factors and that
their E3 ligase activity is integral to this role [46]. The ﬁnding that
Ecto/Tif1-c is regulated by chromatin opens new questions about
how Smads themselves interact with chromatin such as: what
are the histone modiﬁcations promoted by Smads and what are
the epigenetic contexts in which Ecto/Tif1-c regulation of Smads
is permitted or prohibited?
Regulation of Ecto/Tif1-c at the chromatin level also provides an
explanation for the observation that Smad4 in most cells is not
completely ubiquitylated: monoubiquitylation occurs on the frac-
tion of the protein that is transcriptionally-active. In this model
Ecto/Tif1-c primarily acts at the promoter by creating an equilib-
rium between Smad complexes containing Ecto/Tif1-c that are
readily inactivated and pure Smad complexes that successfully
engage in transcription.
According to this model, there would always be a fraction of the
pool of Smad4 in a cell that is inactive. This is consistent with
observations that Smad4 availability is context dependent. On
the one hand, cells have at their disposal a wide amount of Smad4
such that in vitro only very efﬁcient Smad4 knockdown can unveil
the requirement of Smad4 for TGF-b responses [47]. On the other
hand, evidence suggests that the amount of Smad4 available for
signaling is limited in vivo, such that Smad4 heterozygosity is suf-
ﬁcient to unveil its tumor-suppressive functions and in some cases
BMP-induced and TGF-b-induced Smads compete for a seemingly
limited pool of Smad4 [48,49]. Thus, perhaps some factors entrap
Smad4 in an inactive pool and the remaining free Smad4 is regu-
lated by monoubiquitylation. Candidates for Smad4 entrapping
factors are Sno-Ski family proteins. These proteins require Smad4
interaction for their TGF-b inhibitory functions [50] and they can
regulate Smad4 monoubiquitylation [36]. Collectively, these bio-
chemical studies point to the modulation of Smad4 activity as a
key step in the cellular regulation of TGF-b signal transduction,
acting in parallel to the regulation of R-Smad phosphorylation.
Overall, it appears that TGF-b stimulation sets the maximum pos-
sible R-Smad activity in a cell but the response will be precisely
determined by Smad4 availability.
5. Genetic evidence in support of Smad4 regulation byEcto/Tif1-
c and FAM/Usp9X
The regulation of Smad4 by Ecto/Tif1-c was further docu-
mented in vivo by studies of early mouse embryos. Analysis of
Ecto/Tif1-c homozygous knockout mice (Ecto/) showed that lack
of an intracellular Smad antagonist caused embryonic defects thatwere comparable to deregulation of Nodal, the primary TGF-b
ligand in the early embryo [41]. Ecto/ embryos die at the time
of gastrulation and show phenotypes caused by unrestrained
Nodal effects on extraembryonic tissues. In particular, the induc-
tion of the anterior visceral endoderm (AVE) by Nodal occurs in a
much broader domain than normal, as shown by the increased
expression of the Smad targets Lefty1 and Cerl1 (Fig. 2). Consistent
with the biochemical characterization of Ecto/Tif1-c as a Smad4
antagonist, for the AVE phenotype Smad4 is epistatic to Ecto/
Tif1-c: double Ecto/; Smad4/ embryos are equal to
Smad4/ embryos [41].
In mouse embryos, the AVE plays a key role in setting the ante-
rior–posterior axis: Lefty1 and Cerl1 encode for secreted Nodal
S. Dupont et al. / FEBS Letters 586 (2012) 1913–1920 1917antagonists that diffuse into the anterior epiblast abutting the AVE
and prevent Nodal from inducing mesoderm differentiation. In
Ecto/ AVE, overproduction of Lefty1 and Cerl causes, as a sec-
ondary event, a nearly complete inhibition of Nodal ligands that
are active in the epiblast. As a consequence Ecto/ embryos do
not form mesoderm. Thus, in Ecto/ embryos, a precocious
excess of Smad signaling in AVE cells results in lack of Nodal/
TGF-b signaling to epiblast cells at later time-points. This causal
relationship was supported by the observation that genetic reduc-
tion of Nodal in Ecto/ embryos led to normal AVE induction and
the rescue of mesoderm differentiation [41].
Ecto/ embryos also have phenotypes that are the opposite of
those caused by the loss of R-Smads in AVE cells: lack of AVE
induction or Lefty1/Cerl expression and unrestrained mesoderm
induction in the epiblast [51]. Further analyses showed that lack
of mesoderm in Ecto/ embryos is speciﬁcally due to a direct
effect of Ecto/Tif1-c in AVE cells. Tissue-speciﬁc inactivation of
Ecto/Tif1-c only in epiblast cells showed a different phenotype –
normal posterior mesoderm induction with expansion of anterior
primitive streak derivatives. This phenotype is consistent with en-
hanced Nodal signaling (whose maximal dose is required to induce
anterior primitive streak) and is the opposite of phenotypes seen
with epiblast-speciﬁc inactivation of Smad4 [52]. Together, these
data indicate that negative regulation of Smad4 is essential for
the correct interpretation of TGF-b signaling in embryonic tissues.
Further, in the AVE of Ecto/ embryos Smad target genes were
dramatically enhanced, but without overt changes in the expres-
sion of Nodal or in the intensity of Smad2 phosphorylation. In other
words, this is an example of cellular interpretation of a TGF-bmor-
phogen signal that depends on variation in the cellular perception
of the signal, rather than on its extracellular concentration.
Inactivation of Ecto/Tif1-c in mouse adult tissues indicates that
this protein has additional functions. For example, tissue-speciﬁc
inactivation of Ecto/Tif1-c in the pancreas and liver unveiled a
tumor-suppressive function [53,54] that was unexpected from
the deletion of a TGF-b antagonist. In zebraﬁsh, Ecto/Tif1-c was
identiﬁed as the affected gene in the moonshine mutant that dis-
plays defective red-cell progenitor survival [55]. For this pheno-
type, it was subsequently proposed that Ecto/Tif1-c serves as a
positive R-Smad cofactor in a Smad4-independent TGF-b pathway
[56]. However, this is at odds with data from mice with inactiva-
tion of Ecto/Tif1-c in hematopoietic stem cells. These mice initially
display normal circulating red-cell parameters but developed a
progressive myeloproliferative syndrome leading to leukemic con-
ditions and unbalanced hematopoietic stem cell differentiation
within the bone marrow [57,58]. A recent re-examination of zebra-
ﬁsh moonshine mutants uncovered defects in the myeloid lineage
that are more similar to those observed in mice [59], suggesting
a conserved function of Ecto/Tif1-c in the vertebrate hematopoietic
system. Moreover, at least for the erythroid phenotype, a zebraﬁsh
genetic screen identiﬁed the PolII-associated factors pTEF-b and
FACT as required downstream of Ecto/Tif1-c. This suggested that
Ecto/Tif1-c acts by promoting transcriptional elongation at pro-
moters of erythroid differentiation genes [60], although the
speciﬁc transcription factors recruiting Ecto/Tif1-c to chromatin
and any requirement of its RING and PHD-Bromo domains remain
unknown. Collectively, the data indicate that Ecto/Tif1-c likely reg-
ulates transcription factors other than Smads. Thus it is important
to dissect to what extent regulation of TGF-b, BMP or other factors
inﬂuence the various Ecto/Tif1-c mutant phenotypes.
Regarding the genetic validation of FAM/Usp9x as a Smad4
deubiquitylase, it is important to note that Drosophila Fat facets
(homolog of FAM/Usp9x) is a well known regulator of cell fate
[61]. During eye development Fat facets regulates ubiquitylation
of the endocytic adaptor Liquid facets/Epsin inﬂuencing the Recep-
tor Tyrosine Kinase/Ras and Notch pathways [62,63]. Subsequentstudies identiﬁed a requirement for fat facets during development
of larval neuro-muscular junctions and found that this was accom-
plished by opposing the activity of the E3 ligase Highwire [64], a
negative regulator of Gbb/BMP signaling [16]. Building upon this
initial connection between Fat Facets and BMP signaling, experi-
ments exploiting Drosophila wing development showed that over-
expression of Fat facets produced vein overgrowth phenotypes that
are typically caused by ectopic Dpp/BMP signaling [25]. Most
recently, a closer examination of embryos generated by transhet-
erozygous combinations of several fat facets mutant alleles uncov-
ered a previously unsuspected requirement for fat facets in Dpp/
BMP signaling during dorsal–ventral patterning [65]. We observed
that a subset of fat facets mutants resemble dpp mutants and that
introduction of a fat facetsmutation enhances the phenotype of dpp
mutants. These new results suggest that regulation of Smad4,
Medea in ﬂies, by ubiquitylation and deubiquitylation is an evolu-
tionarily conserved mechanism by which cells interpret TGF-b
morphogen gradients.
Interestingly, Ecto/Tif1-c is not cleanly conserved in ﬂies. The
closest ﬂy protein, Bonus, is equally related to the triplicated mam-
malian Tif1 proteins by sequence but appears functionally most
similar to Tif1-a/Trim24 [66]. The lack of conservation implies that
another Medea ubiquitin ligase exists opposite Fat facets to modu-
late Dpp/BMP signaling during embryonic dorsal–ventral axis
formation.
6. Monoubiquitylation of R-Smads and their deubiquitylation
by Usp15
Recently, the ubiquitylation pattern of R-Smads was revisited.
This study found that a previously unappreciated aspect of their
regulation occurs by oligoubiquitylation. Utilizing a scheme similar
to the one that ledus to FAM/Usp9x, the deubiquitylase Usp15 was
identiﬁed as an important factor for R-Smad activity [26]. Usp15 is
required in multiple cellular contexts for Smad transcription and
for TGF-b/BMP-induced responses including cell migration and
germ layer patterning in Xenopus embryos. Consistent with this,
a role for Usp15 in dorsal–ventral patterning (and by extension
BMP signaling) was recently proposed in zebraﬁsh [67].
Mechanistically, Usp15 interacts with R-Smads of the TGF-b (i.e.
Smad2/3) and BMP (i.e. Smad1/5/8) branches and opposes their
ubiquitylation. In the absence of Smurf overexpression R-Smads
are primarily monoubiquitylated on two lysines that are essential
for DNA recognition (K33 and K81), such that monoubiquitylation
of R-Smads was sufﬁcient to prevent DNA binding. It was thus pro-
posed that Usp15 primarily functions by opposing R-Smad
monoubiquitylation and that this sustains their DNA binding
activity. This ﬁnding is supported by the observation that in
absence of Usp15, R-Smads were less efﬁciently recruited to target
promoters in ChIP assays. In contrast, upstream events in TGF-b
signaling such as subcellular Smad2/3 localization and formation
of endogenous R-Smad/Smad4 complexes were unaffected by the
loss of Usp15. Overall, it appears that monoubiquitylation of
R-Smads, in the absence of degradation and independent of overt
effects from phosphorylation-dephosphorylation, is sufﬁcient to
control R-Smad activity (Fig. 3A).
In addition, Usp15 differentially inﬂuences the transcriptional
activity of Smad2/3 complexes as shown by the fact that it has only
minor effects on promoters when other transcription factors pro-
vide the central DNA binding platform (such as FoxH1 on the
Mix.2 reporter). Previously differences in Smad transcriptional
activity were assigned to preferential regulation of some promot-
ers by Smad3 (able to bind DNA directly) and others by Smad2
(unable to directly bind to DNA). This led to the idea that Smad2
and Smad3 may play non-redundant roles in TGF-b signal trans-
duction. This hypothesis is however inconsistent with genetic
Fig. 3. Ubiquitylation and regulation of R-Smads. (A) Monoubiquitylation of R-
Smads inhibits their association with a Smad binding element (SBE) in a target gene
promoter (blue arrow). This inhibition is reversed by the deubiquitylation of R-
Smads by Usp15 (green arrow) that stimulates Smad complex transcriptional
activity. (B) Model for potential relationship betweenmono- and polyubiquitylation
of R-Smads. Polyubiquitylation might occur either by elongating an existing
monoubiquitin via an E4 ligase or stimulated directly by an E3 ligase distinct from
the one inducing monoubiquitylation (blue arrows – ubiquitin addition). Usp15
may oppose all of these reactions (green arrows – deubiquitylation). Extracellular
signals or the cell-intrinsic context may regulate each of these three processes
positively or negatively.
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rescued phenotypes due to Smad2 inactivation and did not cause
any defects in otherwise wild type mice [68]. Nevertheless, the
potential for direct versus indirect R-Smad recruitment to, or inﬂu-
ence on, promoter DNA remains a possibility. From this perspec-
tive, R-Smad monoubiquitylation may represent a means of
inhibiting R-Smad activity on selected promoters while leaving
them active on others. Thus, R-Smad monoubiquitylation may
function as a switch between different TGF-b induced gene-
expression programs.
In the future, it will be interesting to learn how monoubiquity-
lation of R-Smads is regulated, and if this regulation represents a
new point of crosstalk between TGF-b signaling and other path-
ways. Some reports suggest the possibility that DNA damage might
be one of these. Usp15 has been identiﬁed as an ATM phosphory-
lation target in cells upon irradiation [69], raising the possibility
that DNA damage might activate Usp15 activity to foster Smad
activity and induce cell-cycle arrest.
HECT-domain proteins are strong candidates for E3 ligases
stimulating R-Smad monoubiquitylation. Usp15 is both necessary
and sufﬁcient to oppose R-Smad polyubiquitylation as well as deg-
radation induced by Smurf overexpression. Further, a mixture of
recombinant Smurf2/Nedd4 can ubiquitylate Smad3 in vitro and
promote its detachment from DNA. This effect mirrors depletion
of Usp15 (inhibits R-Smad binding to chromatin) and correlates
with decreased DNA binding activity of puriﬁed monoubiquitylat-ed Smad3. Lastly, Smad3 monoubiquitylation appears dependent
on endogenous Smurf2 in mouse MEFs [70].
These recent data suggest that R-Smad monoubiquitylation is a
physiologically relevant mechanism of regulation. However, to
date R-Smad ubiquitylation was studied in the context of polyub-
iquitylation and degradation [13,14]. There are several possibilities
for the relationship between poly- and monoubiquitylation for
R-Smad proteins. First, polyubiquitylation may be a parallel input
to monoubiquitylation, occurring at different lysines and Usp15
may oppose both modiﬁcations. Second, R-Smad polyubiquityla-
tion may represent a secondary event taking place in particular
contexts requiring total R-Smad degradation. In this scenario, per-
haps linker phosphorylation or other inputs inﬂuence the resi-
dence of Smurfs on R-Smads thus determining the balance
between monoubiquitylation (occurring quickly) and polyubiqui-
tylation (requiring more stable ligase-target interaction). Third,
Smurfs could work in some systems as E4 ligases (ubiquitin chain
extenders), acting downstream of an as yet unidentiﬁed E3 ligase
responsible for R-Smad monoubiquitylation. The homolog of
Usp15 in yeast, Ubp12, was identiﬁed as a resident subunit of
the CSN/COP9 signalosome, an important regulator of cullin–RING
ubiquitin ligase complexes [71]. The availability of cullin-speciﬁc
inhibitors [72] enables testing of cullin ligases in opposition to
Usp15 in R-Smad monoubiquitylation (Fig. 3B).
Addressing these issues will require better characterization of
the genetic requirements of HECT ligases in general and Usp15 in
particular and then testing for possible interactions. Regarding
Usp15, the phenotype of knockout mice has not yet been reported
and the extent of overlap with the similar deubiquitylase Usp4
[73] is unknown. Regarding Smurfs, genetic requirements in
Dpp/BMP signaling are well known in Drosophila [74,75] but are
missing in mammals. With regard to mammalian Smurfs, the
redundancy between Smurf1 and Smurf2 and their roles in JNK
signaling and planar cell polarity [76,77] represent complicating
issues in assessing the function of the protein in vivo. In addition,
the effect of other HECT-domain family members on TGF-b sig-
naling may provide further redundancy even though single mu-
tants for HECT ligases in mice and Drosophila do not phenocopy
TGF-b/BMP mutants [78]. Another approach to understanding
the role of HECT ligases in vivo is the mutation of the R-Smad
linker phosphorylation sites that, according to current models
[79–82], should render them resistant to HECT-mediated polyub-
iquitylation. However in the mouse, mutation of the linker phos-
phorylation sites of Smad1 do not generate phenotypes due to
enhanced BMP signaling and this mutation in primordial germ
cells mimics Smad1 loss-of-function [83].
Finally, a cautionary note since our understanding of the effects
of HECT ligases has recently shifted from total R-Smad degradation
to regulation of the activity of phospho-R-Smads [79,80]. Given
that it has been proposed that Smurfs and other HECT proteins
act not only on R-Smads but also on TGF-b receptors [84,85], this
leads to difﬁculty in concluding whether these protein inﬂuence
R-Smad activity directly or indirectly via the receptors. The impor-
tance of ubiquitylation (and thus potentially of HECT ligases) for
receptor regulation has been independently conﬁrmed by the role
of the deubiquitylase Uch37 in protecting TGF-b receptors from
degradation [86,87]. Uch37/Uch15 knockout mice die shortly after
gastrulation and it will be interesting to determine if this pheno-
type relates to TGF-b signaling [88].
7. Cycles of mono- and deubiquitylation are at the core of Smad
regulation
Collectively, these recent studies indicate a key role for
monoubiquitylation in the regulation of Smad complexes by
S. Dupont et al. / FEBS Letters 586 (2012) 1913–1920 1919targeting protein–protein interaction surfaces or by inhibiting their
DNA binding activity. Monoubiquitylation of Smads can occur ‘‘in
solution’’ before nuclear Smad4 and phospho-R-Smads form a
complex on DNA or while Smad complexes are engaged in tran-
scription. Thus monoubiquitylation may provide a system for ac-
tively disrupting Smad complexes and switching off
transcription. This hypothesis, together with the active role played
by deubiquitylases in TGF-b signaling, suggests that Smad
monoubiquitylation is subject to on/off cycles that control the per-
ception of TGF-b signals in several contexts.
This model begs the question – why are Smads engaged in
these cycles? Mechanisms keeping Smad complexes dynamically
unstable were originally proposed to explain the TGF-b pathways
ability to induce different genetic programs based on the inten-
sity of the signal – for example in a morphogen gradient. For this
to happen, two conditions need to be met. First, the number of
receptor complexes activated at the plasma membrane must be
kept proportional to the extracellular concentration of the ligand;
this is likely ensured by the existence of multiple feedback
mechanisms that regulate receptor endocytosis, their persistence
in early endosomes, and the ratio of post-endocytosis recycling
versus degradation. Indeed, the TGF-b pathway antagonists
Smad6/7 and Smurfs are early targets of Smad transcriptional
activation representing a potential feedback mechanism to shut
down R-Smad activation after the initial response and allow the
system to determine if the signal is sustained or has ceased. Sec-
ond, nuclear Smad complexes must not be too stable over time,
so that R-Smads constantly get dephosphorylated, shuttle back
to the cytoplasm and are available for another round of phos-
phorylation should the signal persist. These two mechanisms al-
low Smad activity to be kept proportional to TGF-b signal
concentrations that change not only in space (between neighbor-
ing cells) but also in time.
What is the molecular nature of the nuclear mechanism that
continuously dissociates Smad complexes? R-Smad degradation
as well as dephosphorylation have been proposed to fulﬁl this role,
although it is still not clear at which step in the pathway these
events take place. Dephosphorylation of R-Smads, for example,
was shown to occur independently of R-Smad binding to Smad4
and thus independently of R-Smad binding to DNA [89]. Similarly,
phospho-R-Smad degradation might occur only under particular
circumstances. Thus, Smad monoubiquitylation represents a more
likely mechanism for the disassembly of Smad transcriptional
complexes, allowing them to maintain a dynamic rate of nucleo/
cytoplasmic shuttling and enabling them to repeatedly monitor
ligand/receptor activity.8. Future directions
Additional genetic analyses that interrogate existing biochemi-
cal models are required to extend the observations reported here
and thus expand our understanding of their biological relevance.
More biochemical studies are needed to analyze the interplay be-
tween the different classes of Smad post-translational modiﬁcation
(primarily ubiquitylation and phosphorylation but also sumoyla-
tion and others) and the order in which they occur, so that more
physiologically precise models can be generated for future genetic
testing. For the biochemical experiments, it is becoming more and
more clear that they must consider Smad regulation as a dynamic
process that responds even to subtle variations in TGF-b ligand
concentration [89,90].
In summary, studies to date have shown that the regulation of
Smad signal transducers by mono- and deubiquitylation is a
highly conserved mechanism governing the amplitude of TGF-bsignal transduction and thus TGF-b responsiveness in many cell
types.
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